A-kinase anchoring protein 14Genealiases: AKAP28 · PRKA14
Q-omics provides the consensus-scored AKAP14 profile across patient tissues and cancer cell-line models. AKAP14 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, AKAP14 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, AKAP14 RNA expression shows 7,140 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, LUAD, and TGCT as cancer lineages where AKAP14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKAP14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKAP14 survival associations across molecular data types. AKAP14 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKAP14 RNA expression–survival associations across cancer types. High AKAP14 expression shows favorable associations in BRCA, KIRP, CESC, UCEC, THCA and SKCM. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for AKAP14 RNA expression.
This table summarizes AKAP14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for AKAP14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKAP14 shows lower tumor expression in LUAD and LUSC and higher tumor expression in BRCA, COAD, LIHC and ESCA. The LUAD box plot shows higher AKAP14 RNA expression in normal versus tumor tissue (log2 FC = −1.597, t-test p < 0.001).
This table shows molecular features associated with AKAP14 in patient tissues and cancer cell lines. In patient samples, AKAP14 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, AKAP14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
